1. Scrip
  2. >>Business
  3. >>Strategy

Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas

Teva reported Phase IIb data for its anti-TL1A agent in ulcerative colitis and Crohn’s that the company called transformational and analysts deemed potentially best in class.

Teva logo outside building
Teva reported strong Phase IIb data for its anti-TL1A agent in IBD indications • Source: Shutterstock

Teva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck & Co. in inflammatory bowel disease (IBD). On a same-day call, Teva execs asserted that their drug, duvakitug (TEV‘574/SAR447189), has produced “transformational” data in both ulcerative colitis and Crohn’s disease as the partners look ahead to planning a Phase III program.

Key Takeaways
  • Teva reported that the TL1A-targeting antibody it is developing for IBD with Sanofi hit primary endpoints in ulcerative colitis and Crohn’s in a Phase IIb trial.

In the RELIEVE UCCD study, duvakitug met the primary endpoint of clinical remission in UC with both doses tested, 450mg...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 
• By Anju Ghangurde

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By Jung Won Shin

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

More from Therapy Areas

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.